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The regulation of stem cell research is an issue that has drawn much comment, 
criticism and even judicial arbitration in recent years. An emerging issue, addressed in 
this article, is how the fruits of that research—stem cell medicine—are likely to be 
regulated en route from lab to market. Taking account of the ethical, legal, social and 
safety issues raised by stem cell medicine and the goals of governance, the article 
explains the relevant regulatory instruments (e.g. the draft UK Stem Cell Bank Code, 
the EU Directive on Human Tissue, the EU Directives on medical products and 




Human stem cell research is an energetic and vibrant field of science across the world 
– not least in the UK, US, Israel, China, Japan and Australia. Nevertheless, it is also 
something of a political, ethical, social and legal minefield, creating challenges for 
regulatory bodies, policy makers and scientists as they traverse their way through a 
tangled web of regulations and moral prosthelytizing. Profoundly difficult questions 
surround the morality of destroying embryos or using the remnants of aborted 
foetuses to improve the medical welfare of other human beings, and the morality of 
cloning human beings to improve the efficacy of the technique.2 There has been 
extensive public debate about these topics,3 which led to two pieces of legislation in 
the UK,4 numerous legislative amendments in other countries,5 and calls for an 
international resolution by the UN General Assembly.6  
But whilst there has been much commentary on the regulatory framework that is 
needed to govern the derivation of stem cells, there has been negligible discussion of 
the regulation that will govern how the results of this research—stem cell medicine—
will get from lab to market. This article investigates this question. It seeks to explain 
how stem cell medicine is likely to be regulated, and to identify areas where further 
attention is required. These issues are significant as the UK has recently established a 
special Stem Cell Bank which will be the first in the world to curate standardized 
human adult, foetal and embryo stem cell lines on a single site. 
We have structured our discussion in the following way. First, we draw attention to 
the issues that ought to be addressed by the regulatory system given the foreseeable 
characteristics of stem cell medicine. Second, we consider the regulation that 
currently applies during product development and when seeking market approval.7 In 
this section we focus on the regulatory system that is developing in the UK. On the 
question of stem cell research, the UK is widely regarded as having produced some of 
the most sophisticated regulatory solutions. Its cautiously liberal approach has also 
positioned it as a world-leader in the development of stem cell medicine.8 
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Furthermore a series of new initiatives (e.g. the UK Stem Cell Bank, the East of 
England Stem Cell Network and the Cambridge Stem Cell Institute)9 and new legal 
policy from the UK and European Parliaments mean a concerted effort to regulate 
regenerative medicine is already underway. Some £16.5 million of public funding10 
and £200 million of further funding from the private sector have been earmarked for 
research related to the development of stem cell medicine.11 These features make it a 
particularly interesting and relevant case study for the future regulation of stem cell 
medicine. In the final section we reflect on some of the tensions and gaps that remain 
in the fledgling UK regulatory system.  
 
Regulatory Objectives  
1 Potential medical applications of stem cell research 
Stem cell medicine can be described as strategies for successful regenerative medicine 
to treat diseases and abnormal conditions of the human body. The idea common to all 
stem cell medicines is that they exploit the pluripotency of stem cells, which are cells 
that replicate in an undifferentiated state for long periods of time whilst retaining the 
potential to develop into most tissues of the human body. If current research is 
successful, scientists will be able to trigger stem cells to develop into different kinds 
of tissue. Newly generated tissue could then be transplanted to reconstruct diseased or 
dead tissue or to correct tissue function. Clinical applications might also be developed 
to stimulate patients’ own stem cells in situ, for example to prevent osteoporotic 
fractures.12  
Research is presently being conducted on a wide range of clinical applications. 
Examples include research to develop blood and bone marrow cells for treatment of 
blood diseases; pancreatic islet cells for diabetes; neural cells for nervous system 
repair; tissues to repair blood vessels; and engineered tissues to enhance ordinary 
tissue function.13 Most of this research is still at an early stage, though stem cell 
medicine derived from fetuses has been the subject of clinical trials in the US14 and 
cell lines are in preclinical development for studies with Huntington’s Disease and 
sufferers of stroke.15 Researchers are keen to develop methods of deriving stem cell 
lines from human embryos cloned from an adult donor, using cell nuclear transfer. 
These stem cell lines are more likely to be immunologically compatible with the 
donor. Thus far, clinical-grade human embryonic stem cell lines have not been 
developed.16 Since most countries restrict or prohibit the use of embryos in research, 
further experiments are being done to investigate the pluripotency of stem cells 
obtained from adults and fetuses.17
There are a number of scientific challenges.18 Most significantly, stem cells 
must be retrieved without damaging them, coaxed to create a stable cell line, and 
stimulated to differentiate into the tissue of choice. Having created the tissue of 
choice, it must be separated from the culture and reagents, transplanted to the area of 
the body without destroying or destabilising it, and made to integrate with other cells 
and the vascular system in the area of the transplant. It is important that the 
transplanted tissue does not infect the patient with a disease from the original stem 
cell or tissues used to culture it. Establishing inter-cell communication is also 
significant so that the transplanted stem cell tissue does not prompt an untreatable 
immune reaction or grow in an unresponsive way to create a tumour. 
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2 Emerging issues for the regulatory system 
The purpose of regulation, broadly conceived, is to facilitate a social goal—in this 
case the commercialisation of stem cell medicine—whilst addressing social risk, 
market failure and concerns of equity and morality through rule-based direction of 
social and individual action.19 On one view it involves three generic sub-objectives. 
First, regulation must reassure the end-users (patients and health care providers) that 
the product will reliably satisfy their needs without creating undue cost or moral 
concerns. In addition to stimulating rational demand, regulation also needs to 
stimulate supply.  That is, it must reassure those who supply raw materials and labour 
that it is an enterprise in which it would be rational to participate. In the case of stem 
cell medicine, biotech companies provide the labour and some raw materials. 
However, critical raw material—stem cells and oocytes—must be provided by 
ordinary people (some from IVF programs, some self-donors, some with unusual 
cells,20 and some people off the street). A different set of conditions will be needed to 
attract their participation. A third objective of regulating commercialisation (often 
overlooked by economic analysis) is the importance of encouraging responsible 
manufacturing processes. This is the glue that holds the regulatory system together, 
securing compliance with the spirit of legal policy rather than companies doing ‘what 
they can get away with’. 
(a) Reassuring End-users  
(i) Safety and quality 
End-users are primarily concerned that the innovative stem cell medicines have a high 
level of safety and quality, and will not be detrimental to their health. In this regard, 
regulation will need to ensure that cell lines used as the basis for stem cell medicines 
do not carry an infectious disease, viral disease or mycoplasma contamination.21 
These might be transferred to the recipient of the stem cell transplant. At a research 
level, mouse feeder cells are often used to help culture human stem cell lines. These 
may have negative or unknown side effects in humans. Moreover, transplanting 
animal cells into humans raises the legal and ethical issues surrounding 
xenotransplantation. It is difficult to separate the mouse feeder cells once they have 
been used as a culture, thus regulation is needed to ensure appropriate culture bases 
are used for clinical-grade stem cell lines, and that research-grade and clinical-grade 
cell lines are kept separate. Similar steps are necessary to ensure that the reagents used 
during the cultivation of stem cell medicines are safe for human use. Two further 
issues relevant to the safety of the stem cell medicines are tumourgenicity and 
antibiotic use. These must be quantified and within acceptable levels. Antibiotics are 
commonly used to identify cells of interest in a culture or to clean up contamination, 
however this can interfere with inter-cell membrane communication or lead to 
antibiotic resistance.22  
Stem cell medicine may also challenge typical assumptions about the relative 
risks posed by autologous23 and allogeneic cell transplants.24 The former are routinely 
regarded as less risky because there is less chance of infection and immune reaction, 
and the process is usually carried out within one institution. A question raised by stem 
cell medicine is whether cell lines from cloned embryos are to be regarded as 
autologous (i.e. a transplant from/to the same person), and whether they are indeed 
less risky.  
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To ensure stem cell medicines are of a satisfactory quality, regulation should 
insist that cell lines have stable characterizations in order that the safety risks are 
predictable. Relevant indicators include karyotyping and chromosomal analysis, gene 
expression, proliferative properties, bioassays and telomerase activities.25 Current 
indications are that freezing and thawing cell lines can affect stem cells’ 
characterisation, therefore conditions of storage should also be addressed. 
(ii) Clinical efficacy or performance of claims 
Promoting high levels of quality and safety in stem cell medicine is a highly technical 
issue, but there is much agreement that this is an important goal.  A more 
controversial issue is whether stem cell therapies should be required to show that they 
have equivalent or better therapeutic potential than other therapies already on the 
market. Alternatively, we might be satisfied if regulation simply stipulates that stem 
cell medicines must do what the manufacturer claims they will do (e.g. replace 
diseased tissue with tissue of a certain characterization). These contrasting standards 
are sometimes referred to as, respectively, ‘efficacy’ and ‘performance’. The 
distinction goes to the heart of the difference between the regulation of medical 
products and medical devices. Medical devices (e.g. pacemakers and syringes) are 
required to show that they perform in the way the manufacturer claims and in this 
sense are regulated in a similar fashion to non-medical engineered products.26 The 
question of efficacy is left largely to market forces; if the device is less useful than 
other therapies, consumers will not purchase it. In contrast, medical products 
(stereotypically, pharmaceutical drugs) are required to fulfil the more demanding 
criteria of efficacy,27 and to this end manufacturers will more often be required to 
conduct clinical trials. Whether the regulatory system opts for performance or efficacy 
will be a particularly pertinent issue for a stem cell medicine if it carries a risk of 
causing abnormalities (e.g. tumours) which other alternative therapies based on drugs 
or live-transplant do not. 
(iii) Cost-efficiency 
The regulatory framework for stem cell medicines will also need to attend to the issue 
of cost-efficiency if it is to satisfy end-users. The health system has a variety of 
mechanisms to investigate the cost-efficiency of medicines (e.g. the National Institute 
of Clinical Excellence), but the most fundamental approach is to stimulate a 
competitive market. The general theory is well known. Where there is competition 
between sellers, consumers get a better deal. The sellers vie with one another to 
produce a better product at a cheaper price. The important drivers are that there should 
be enough sellers to provide a range of products at alternative prices, and informed 
consumers who rationally choose between the products on offer.  
Innovative technologies like stem cell medicine pose difficulties for a properly 
functioning market. There may be few companies with the necessary know-how, new 
players may be inhibited by the regulatory burden, and consumers may lack the ability 
to distinguish the better product from a worse one. Consumers are especially likely to 
be information-poor if manufacturers are not required to prove the efficacy of their 
product prior to market approval. Thus there is a complex tension between keeping 
regulatory burdens low, and having enough regulatory intervention to protect 
unsuspecting consumers.  
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(iv)  Embryo origins  
It is also foreseeable that end-users will be concerned about the origins of a stem cell 
medicine, in particular whether it is based on an embryo stem cell line. Should 
regulation stipulate that users should be carefully briefed about the fact that the 
medicine was produced from embryos? The extensive debate in this country and 
many others about the use of embryos in research suggests that a considerable number 
of people are unhappy with the prospect of using embryos for medical ends and would 
want to be carefully briefed about the provenance of the therapy and have the 
opportunity to refuse to use therapies built from dead embryos. An analogy would be 
the respect that is given to the decisions of Jehovah's witnesses to refuse the 
transfusion of blood or primary blood products.28 On the other hand, perhaps this 
approach would be unduly cautious.  After all we are rarely, if ever, informed whether 
medicines have been tested on primates and given an opportunity to refuse or consent 
on the basis of that knowledge though some people find experiments that use higher-
order primates morally troubling. Does this fail to respect us as morally autonomous 
beings? Perhaps we are satisfied to receive medicines based on the understanding that 
the regulatory system has considered the issues, and has set and monitored standards 
that are reasonable for a morally pluralist society.29  
(v)  Social impact 
A further issue which end-users might be concerned to see addressed by regulation is 
the justice of stem cell medicine and its impact on social relations. It has been 
suggested that minority ethnic groups are unlikely to benefit equally from stem cell 
medicine if stem cell banks fail to include the less common tissue haplotypes.30 
Furthermore, stem cell medicine may be a cost-intensive technology that only the 
wealthy will be able to afford. In the longer term it is possible that stem cell medicine 
may significantly extend average life expectancies, which has attendant social 
complications. For instance, pension payments and inter-generational family disputes 
could increase dramatically.  
(b) Reassuring Suppliers 
(i)  Property, intellectual property and minimal regulation 
By and large, companies that provide labour and materials will be reassured by the 
regulatory system if it includes mechanisms that provide for clear and secure chains of 
title, allows them to recoup investment through intellectual property, and keeps 
regulatory burdens minimal.  
(ii) ‘Respect’ for tissue, consent and minimum standards 
Securing the trust of members of the public who are the source of the precursor tissue 
for the stem cell lines may be more challenging. Donors of tissues may consider their 
tissue to have a value different from the value that researchers and manufacturers 
attach to it. Donors may project some of the significance they place on their identity, 
reproductive capacities, physical integrity, and immortality onto the tissue that they 
are asked to donate for the purposes of stem cell medicine. That is, they may see the 
tissue as more than the sum of its biological parts.31 Their attitudes are likely to be 
highly variable and policymakers will need to consider how they should regulate in 
the face of reasonable pluralism. 
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(iii) Incentives for stem cell donations 
There is more debate whether regulations should provide incentives to make people 
more willing to donate their tissues, for example by paying them, or giving them some 
other benefit in return. Some are concerned that this would lead to an unethical level 
of commodification that belittles human existence, or undermines altruism.32 Others 
have argued that safety is compromised when financial incentives are offered since 
donors will have a reason to hide information about their medical histories. 
(iv) Confidentiality and feedback 
Medical testing is part of the process of donating tissue for stem cell medicine, in 
order that the safety and quality of the tissue can be assessed. This involves screening 
for certain infectious diseases and genetic traits, and blood typing. This produces 
sensitive information that many donors may or may not wish to know, nor wish others 
to know. Therefore, the regulatory framework will need to protect the confidentiality 
of donors and set standards relating to feedback of information.33  
(c)  Encouraging Responsible Manufacturing Practice 
Mechanisms to ensure responsible manufacturing practice are difficult to define 
precisely or exhaustively. In large part, the objective is to keep manufacturers 
sufficiently ‘on their toes’ so that they observe the regulatory policy, and sufficiently 
‘sweet’ so that they cooperate with regulators without the need for costly 
prosecutions. In practical terms, this means stimulating a healthy level of competition, 
keeping regulatory burdens to a minimum, providing incentives in the form of 
intellectual property or free regulatory advice, and enforcing the regulatory 
framework sensibly (i.e. without extreme formalism or undue regulatory ‘slack’).34 A 
pyramid system building up from self-regulation, registration and licensing, civil 
liability and finishing with a few criminal penalties for the worst breaches is argued 




Regulation: From Lab to Market 
 
We turn now to consider the regulatory system emerging in the UK, as influenced by 
European and national legislation and policy. 
1 Product Development  
(a) EU Tissue Directive 2004 
European Member States recently (March 2004) agreed, after protracted debate within 
the European legislative machinery, a common regulatory framework to ensure the 
safety of cells and tissues that are transplanted into, or onto, the human body.36 One 
reason for the delay was that the European Parliament tried, indirectly, to prohibit 
therapeutic cloning and embryo stem cell research under this instrument.37 Those 
provisions were eventually discarded.38 The directive—titled “on setting standards of 
quality and safety of the donation, procurement, testing, processing, preservation, 
storage and distribution of human tissues and cells”—will apply, amongst other 
things, to stem cell medicines but not the preceding in vitro research. Member States, 
and therefore the UK, are obliged to implement the directive by April 2006.  
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The Articles most relevant to ensuring clinical-grade tissue development are 
those on testing, processing, donation, and procurement. The precise technical 
requirements are merely outlined in Article 28, and are yet to be decided by the 
Commission, pursuant to the procedures in Article 29. Draft technical requirements 
for donation, procurement and testing have been published for consultation.39 A 
second set of technical requirements on processing, preservation, storage and 
distribution is expected in the near future. It is anticipated these will cover 
requirements for quality systems and coding.40
In broad terms, donated and processed tissue must be tested for infection (e.g. 
HIV, hepatitis and syphilis) and characterized. Living donors of allogeneic tissue are 
required to undergo a prior medical examination and interview. The Directive also 
stipulates that donors should not be paid, for reasons of safety rather than ethics.41 
Matters of ethics were regarded as issues that the European Union was not competent 
to legislate upon.42 Issues of data protection and consent were covered to a limited 
extent. The Directive states that the European Directive on the processing of personal 
data must be observed43 (this is already binding on Member States). It also states that 
the laws on consent in each Member State must be observed when tissue is procured 
from donors.44  
 Safety and quality are addressed in a set of rules on product recall, preservation, 
storage, labeling, packaging and adverse incident reporting.45 No specific provision is 
made for compensation where a patient is harmed by a tissue therapy, although a 
claim might be made through product liability laws, including the law of negligence 
and consumer protection legislation.46 It is doubtful however that these laws will 
assist an end-user who suffers emotional distress on finding out that they were treated 
with a product derived from embryos, but does not develop a recognized psychiatric 
condition.47  
To ensure that the rules are adhered to and that the premises are suitable for the 
development of clinical-grade tissue therapies, each Member State is responsible for 
seeing that establishments that handle relevant tissue are licensed and follow a quality 
assurance system. Strict rules on the traceability of product development will also 
apply to achieve rigorous accountability. 
The Directive does not apply to autologous grafts within the same surgical 
procedure.48 The latter phrase is significant. For instance, if autologous tissue is 
banked it is covered by the Directive.49 This suggests embryo stem cell medicine is 
likely to be covered by the Directive, whether or not it is considered an autologous 
procedure, since the activity required to clone a blastocyst is likely to require more 
than a single surgical procedure. 
(b) Human Tissue Act 2004 
Until the directive is implemented the standards noted above have no legal equivalent 
in the UK, aside from laws that protect donors of tissue. These laws, most notably the 
Data Protection Act 1998 and (until recently) the Human Tissue Act 1961, have been 
the source of much debate. Parliament has recently repealed the latter after the furore 
following the non-consensual retention of organs following post-mortems at hospitals 
in Bristol, Liverpool and elsewhere.50 It has enacted in its place a much more 
extensive piece of legislation, the Human Tissue Act 2004 (HTA), which is expected 
to commence in April 2006. The fundamental principle underpinning this Act is that 
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individuals should have the opportunity to choose whether or not tissue lawfully taken 
from their bodies is subsequently retained or used for medical research. Accordingly 
the Act makes it a criminal offence to use human tissue (excluding gametes and 
embryos) in research without the prior consent of the individuals. The Act also 
regulates tissue disposal, trafficking of controlled materials, and DNA analysis of 
tissue. However, somewhat surprisingly, the government’s Explanatory Memorandum 
indicates that none of the various protections the Act introduces51 apply to human 
stem cell lines by virtue of the clause which excludes tissue ‘created outside the 
human body’.52 This policy decision is perplexing in its ethical dimensions—surely 
donors of tissue for stem cell medicine are entitled to the same protection as donors of 
tissue for orthodox tissue transplants? The policy enacted goes well beyond the 
policies contemplated in the government’s discussion paper preceding the legislation. 
These included the idea that anonymised cell lines might be used or stored without 
consent, or that donors might be asked to give up property and other economic rights 
in cell lines (but not all power to restrict the use of cell lines derived from them).53
(c) Codes and Guidance 
(i) Tissue-related 
To date, the safety of human tissue product development has been regulated by codes 
rather than law. The three principal codes in this regard were prepared by the Medical 
Devices Agency (MDA),54 and the Department of Health.55 The MDA’s code 
includes rules on characterizing quality, batch control, infection controls, risk 
minimization, certificates of raw material analysis, scaffolds, donor screening, cell 
culture preparation, and full passage data. Other rules recommend procedures to 
prevent contamination, tampering and deterioration, and labels that advise on 
handling and hazards. The Department of Health's guidance is equally technical and 
detailed. The Codes were published in 2000 to 2002 and will need to be brought up-
to-date for the purposes of stem cell medicine, particularly if stem cells are combined 
with nanotechnology and genetic technology to develop ‘intelligent’ regenerative 
structures.56 In conjunction with these codes, the Medicines and Healthcare products 
Agency (MHRA) has encouraged therapeutic tissue banks to apply for voluntary 
accreditation.57
(ii)  UK Stem Cell Bank 
As noted, the UK has taken the bold new step of setting up a dedicated national Stem 
Cell Bank. It is the first in the world to curate standardised human adult, foetal and 
embryonic stem cell lines on a single site.58 The Bank will house clinical-grade stem 
cell lines and establish approved facilities for processing them. It issued a Draft Code 
which broadly outlines the criteria to be observed when deriving and using human 
stem cell lines.59 A companion code specifies the conditions for accessing stem cell 
lines in the bank.60  
The Draft Code is ostensibly similar to the standards set out in the European 
Tissue Directive and codes on tissue therapies mentioned above. It also covers 
cryopreservation, import/export, and transportation of stem cell lines.61 The 
International Stem Cell Forum has set up a working group to design indicators 
specially suited to characterizing embryo stem cell lines.62 Sections 5 and 6 of the 
Draft Code set rules covering donor selection, screening, information and consent, 
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and prohibiting payment. The central idea is that donors are asked to gift their stem 
cells, relinquishing all future control, after comprehensive information is provided to 
them about the implications of doing so. A further pre-requisite is that they consent to 
provide a medical history and allow genetic testing. Their data will be kept 
confidential, but traceable. Embryo donors may select one of three conditions for 
feedback on disease that might be discovered in the future (where it concerns their 
sample): no feedback; feedback where there is, or is potentially, a therapy; or 
feedback in any circumstance.63 This contrasts with UK blood donation guidelines 
that, in an effort to minimise the numbers of donations that compromise public health, 
state that putative donors should be told that information about significant abnormal 
results will be fed back to them; blood donors are not permitted to stipulate that no 
feedback should occur.64 To boost accountability to the standards, and avoid conflicts 
of interest, the Bank has decided it will not conduct discovery research itself.65  
Not all stem cell developers will be bound by the Draft Code, only those who 
sign a contract to use stem cell lines from the bank. However, the principles are likely 
to reflect closely the MHRA requirements for market approval (see below), and the 
Medical Research Council (MRC) will require those who receive its funding to 
observe the Bank’s rules.66 The Draft Code will apply more strictly to embryo stem 
cell lines because the Human Fertilisation and Embryology Authority (HFEA) has 
decided that it will make compliance with the Draft Code a condition of all its licenses 
for embryo stem cell research, and will require a sample of all embryo stem cell lines 
to be deposited with the Bank.67 One justification for the differential treatment of 
embryonic and somatic stem cell lines is that mandatory banking will minimize the 
numbers of embryos that are used, which some say is a mark of ‘respect’. 
The level of oversight seems to be tight. Detailed ‘route maps’ show the system 
for accessing a stem cell line.68 The Bank has also indicated that, in relation to 
embryonic stem cell lines, its approval must be obtained before involving new 
collaborators from a different institution or new projects on the same cell line, and it 
should be notified of new and departing staff.69 Nevertheless, the degree of real 
intervention remains unclear; the Bank may do little to enforce these requirements. 
(d) Property and Intellectual Property Rights 
The Draft Code from the UK Stem Cell Bank envisages that stem cell lines will 
remain the property of depositors, and that depositors will negotiate Materials Use 
Licenses with each would-be accessor to protect their proprietary interests.70 
Intellectual property rights can be asserted in these licenses. Some ‘reach-through 
claims’ could be expected (patent claims or license terms asserting a right to a share 
of revenue generated from downstream products, methods and protocols), but these 
are unlikely to be as controversial as reach-through claims stemming from gene 
patents, which cannot be invented around.  
The UK Patent Office is willing to grant patents to applicants claiming 
pluripotent stem cell lines retrieved from human embryos,71 as well as somatic stem 
cell lines (provided the standards of novelty, inventiveness, industrial applicability, 
sufficient disclosure are demonstrated). However, the European Patent Office’s 
Opposition Division has interpreted the wording of the morality clauses in the EU 
Directive on the legal protection of biotechnological inventions differently.72 On its 
view, the same policy would not be lawful under the European Patent Convention.73 
Unless the ruling is reversed on appeal, the implication is that inventors will have to 
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apply to national patent offices in each of the European countries where they hope to 
patent a stem cell line isolated from human embryos.74 Until the interpretation of the 
EU Directive is clarified, individual Patent Offices are likely to adopt differing views 
about the patentability of stem cell lines isolated from embryos. 
 
(e) Confidentiality and Feedback  
Given that the EU Tissue Directive and the various codes stipulate that donors’ 
samples and records should be traceable (meaning their identity is encrypted but 
accessible), it is likely that the data will fall within the definitions of personal data 
(under the Data Protection Act 1998) and confidential information (at common law). 
This would be the case where the data controller (a term defined under the Data 
Protection Act) holds the data encryption key, rather than an independent third party. 
In this case, users of the information would ordinarily need the consent of the person 
or persons who are identifiable from the information in the user’s possession. The 
Data Protection Act 1998 is clear that this should be explicit consent, but neither it nor 
the common law clarify the specific information that must be given to ensure the 
consent is valid. The Annex to the EU Tissue Directive provides some guidance but 
this only applies in so far as it is consistent with Member States’ national legislation 
and thus may not be binding.75 Some scholars have also questioned whether genetic 
screening necessitates a special attitude towards consent, for example that consent 
should be sought from close family members prior to use or disclosure.  
2 Market Approval 
(a) Current Standards for Authorisation 
Before a new medical product can be released, it must be approved for market release 
by the European Commission, or the UK Licensing Authority (Health Ministers) as 
advised by the MHRA. Strictly speaking, a new medical device does not require prior 
authorisation in the same way. A device is either ‘self-certified’ (the manufacturer 
declares the device meets the requirements under the relevant European medical 
device directive) or it passes a conformity assessment process with a ‘Notified Body’ 
(an independent (commercial) body which has been approved by the MHRA as 
suitable for carrying out such assessments). The crucial question is whether stem cell 
medicine is required to meet the criteria of the Medicinal Products Directive76 or the 
less demanding Medical Devices Directive.77 The answer is less than obvious if one 
looks to the central definitions of medicinal products or devices (see boxed figures 1 
and 2).  
 
Figure 1  Definition of Medicinal Product78
 
(a)  any substance or combination of substances presented as having properties for 
treating or preventing disease in human beings; or 
(b)  any substance or combination of substances which may be used in or 
administered to human beings either with a view to restoring, correcting or 
modifying physiological functions by exerting a pharmacological, 
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Figure 2   Definition of Medical Devices79
 
any instrument, apparatus, appliance, material or other article, whether used alone or 
in combination, including the software necessary for its proper application intended 
by the manufacturer to be used for human beings for the purpose of:  
-  diagnosis, prevention, monitoring, treatment or alleviation of disease,  
-  diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap,  
-  investigation, replacement or modification of the anatomy or of a physiological 
process,  
-  control of conception,  
and which does not achieve its principal intended action in or on the human body by 
pharmacological, immunological or metabolic means, but which may be assisted in its 
function by such means 
Against these definitions stem cell medicines appear to be a borderline product. 
The distinction can be important as it affects the stringency of oversight. Furthermore, 
as mentioned, medicinal products are required to show clinical efficacy as well as 
safety and quality, and to this end a manufacturer must conduct clinical trials as 
necessary. With medical devices, on the other hand, manufacturers are (by and large) 
required to show only that a device performs as claimed and that its benefits outweigh 
the risks it poses to users. In practical terms, an evaluation of existing literature will 
frequently suffice and clinical trials are less commonly required.80  
On closer inspection it appears that, at the present time, stem cell medicines will 
be treated as medicinal products since the Medical Devices Directive specifically 
excludes cells and tissues of human origin.81 This categorisation is not an absolute 
rule,82 nor a particularly apt one even after the Medicinal Products Directive was 
amended to include advanced technologies.83 Thus the former UK Medicines Control 
Agency (MCA) and the former MDA (now amalgamated in the new MHRA) both 
took steps to set some indicative standards.84 There are still some ambiguities and 
gaps. Tellingly, both the MDA and the UK Stem Cell Bank recommend that 
‘regulatory guidance should be obtained from the medicinal authorities on cell 
lines/tissues arising from stem cell technologies’.85
Interestingly the codes have narrowed the distance between the concepts of 
efficacy and performance. For instance the MDA code requests evidence that shows 
more than performance and states that ‘where possible’ developers should 
demonstrate ‘a correlation with clinical effectiveness’, and compare the product with 
the best clinical alternative for treatment through randomised clinical trials.86  
(b) Proposed EU Regulation for Human Tissue Engineered Products 
The vagueness within the current regulatory framework has led to considerable 
dissatisfaction:  
“At present, the lack of a comprehensive, clear and uniform regulatory 
framework creates legal uncertainties and leads to a fragmentation of the 
tissue engineering market: similar products are regulated differently in the 
various Member States, different safety requirements may apply and patients 
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can be denied access to products which are readily available in other 
countries.”87  
Some also consider the current rules deficient because the standards they set for 
autologous cell therapies are too lax in some circumstances. In response to these 
concerns, the European Commission has proposed a Regulation for human tissue 
engineered products, which it consulted on in 2002-2004.88 It proposes a single 
regime for human tissue engineered products, clear demarcation from medicinal 
products and devices, and safety standards for autologous and allogeneic tissues that 
reflect levels of risk and minimize regulatory burdens for single application tissues. It 
is expected that a draft Regulation along these lines will be circulated for public 
consultation in 2005.89
(c) Clinical Trials Regulations 2004 
As and when stem cell medicine trials begin, the new UK Clinical Trials Regulations 
(CTR), which came into force on 1 May 2004, will apply.90 This instrument provides 
a statutory footing for good clinical practice, good manufacturing practice, research 
ethics committee review, informed consent of trial participants, and legal liability for 
injuries.91 If a new Regulation distinguishes tissue-engineered products from 
medicinal products, the CTR may need amendment to cover these products. 
 
The Adequacy of Current Regulation 
1 Reassuring End-users  
Many steps have been taken to ensure that the UK regulatory system promotes safe 
and high quality stem cell medicines, and addresses tumourgenicity, stability, 
adventitious agents, antibiotics use, freezing and the like. These apply to tissue 
generally and stem cell medicines specifically. Additional work is underway to 
improve the expertise and consistency of oversight.92 It seems the authorities are also 
taking a holistic approach to the regulation of safety and quality, as evidenced by the 
introduction of regulatory mechanisms that apply long before a product seeks market 
approval and strict traceability.93  
But whilst the issues of safety and quality have been thoroughly and openly 
addressed, other factors relevant to reassuring end-users have been neglected in 
comparison. One oversight has been the failure to discuss how the system will ensure 
compliance. To date, regulation has largely been soft rather than strict until the point 
at which MHRA approval is sought. This may continue even after the EU Tissue 
Directive and the Draft Code from the UK Stem Cell Bank are implemented.94 The 
decision is relevant to the cost-efficiency of the system. The approach needs to 
improve the imperfections of the market, acting on behalf of information-poor 
consumers, without creating a weightier set of problems by adding regulatory red tape 
that hinders competition. The fact that there is only one UK Stem Cell Bank could 
create an anti-competitive bottleneck if it is not managed carefully. In effect, it has a 
monopoly on the banking of embryo stem cell lines and has a heavy responsibility to 
oversee those resources in an efficient manner.  
There is also a question whether the system does enough to ensure 
manufacturers are sufficiently accountable to patients injured by stem cell medicines, 
as opposed to the official regulators. The myriad of codes does little to address this 
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point. The Draft Code merely tries to exonerate the Stem Cell Bank of any 
responsibility, stating that stem cells are provided without any warrant of their 
merchantability or fitness for purpose.95 Whilst consumer protection law might assist 
to some degree, a discussion about its adequacy is noticeably absent in the governance 
documents. These also fail to discuss the interest an end-user has in knowing that a 
stem cell medicine they are offered to them is derived from destructive research with 
embryos. The documents fail to discuss this even in the context of labeling.96 
Similarly, policymakers seem not to have considered the wider social issues relating 
to equity of access and resource allocation which academics have noted as being 
important. Further discussion is needed to establish how these matters might best be 
addressed.  
There is also a lack of clarity on the issue of efficacy versus performance of 
manufacturers’ claims. It is difficult to discern which standards manufacturers are 
required to meet, and it is odd that this issue was not discussed in the consultation 
documents on the proposed Human Tissue Engineered Products Regulation. There are 
empirical and normative issues at stake–for instance, how should one measure the 
efficacy of stem cell medicines; should efficacy be a pre-requisite for market-release 
of such an innovative therapy; and should the data on embryo-derived stem cell 
medicines be made available to the HFEA which must consider the necessity and 
desirability of license applications for the use embryos in research?  
2 Reassuring Suppliers 
In terms of its ability to reassure suppliers, the current UK regulatory system has some 
significant shortcomings, but is not acutely flawed. Policymakers have foreseen the 
issues of property and intellectual property in stem cell medicines. The Draft Code 
which has made provision for Materials Use Licenses, the UK Patent Office and the 
HTA have all taken steps to recognise explicitly developers’ property and intellectual 
property in stem cell lines. Nevertheless, a good deal of uncertainty persists. Case law 
on the amount of skill and labour that is necessary to ground a property claim in 
human tissue is unclear (the HTA has not clarified it); and intellectual property rights 
available under the European Patent Convention (an administratively easier route than 
applying through national offices) are in a state of flux.  
The developers of stem cell medicines must contend with a daunting regulatory 
burden, especially considering the majority of companies in this business are small- to 
medium-size enterprises. The applicable regulations are numerous, complex and 
growing, and their full impact will not be known until methods of compliance and 
enforcement become clearer. It may turn out that the variety of legislation is 
defensible as a tailored ‘pyramid’. The UK Stem Cell Bank, together with its red tape, 
may also turn out to be a boon to smaller businesses if it lowers transactions costs and 
helps them develop compliance tools. We suggest this issue be monitored, and that 
State-sponsored initiatives to explain the regulatory system be introduced.97  
Deeper problems surround the sufficiency of the regulatory system for 
protecting the interests of individual tissue donors. It is remarkable that donors of 
stem cells have the least legal protection of all tissue donors. Despite recent policy 
reform in the form of the HTA and the EU Tissue Directive, UK legislation does not 
stipulate that developers must respect the limits of stem cell donors’ consent. For 
instance, if an individual were to state “I consent to you using my tissue to create a 
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stem cell line, but in years to come I do not wish pharmaceutical companies to have 
access to the cell line because of the way my family was treated in a clinical trial”, no 
liability would follow if the developer did in fact contravene the latter condition. Once 
a stem cell line is created, it falls outside the remit of the HTA. In contrast, conditions 
of consent will be binding under the HTA when other kinds of tissue are used by 
developers and even where pathologists inspect resected tissue for the purposes of 
basic research. If the developer thinks the putative donor’s restrictions are 
unworkable, he or she is expected to avoid criminal liability by declining the tissue 
donation. Developers of stem cell medicines will perhaps decide to work in this way 
as well. But in the event they do not, donors whose tissue is used as a pre-cursor of a 
cell-line are left to rely on common law and the less formal powers of the UK Stem 
Cell Bank and the MRC. The latter two cannot force compliance from companies who 
develop somatic stem cell medicines with private funding and without using cell lines 
deposited in the Bank. Research ethics committees offer another line of protection, 
but at present it is doubtful whether they monitor compliance with consent 
requirements once they have approved a proposal. We leave open the question 
whether strict requirements for consent are the appropriate way to protect individuals’ 
interests in their tissues, but would argue that the exclusion of stem cells from the 
HTA framework deserved considerably more debate. The question for present 
purposes is whether a legislative requirement should be added when the government 
implements the EU Tissue Directive, or whether individuals’ interests in their tissues 
can be properly observed through another regulatory mechanism. 
In terms of paying individual donors for their tissue donations, government 
resistance has shown signs of thawing98 but payments will not be allowed at either the 
UK or EU level where cells or tissues are used for transplantation. It will take a 
groundswell to alter this position now that it has been backed by legislation. 
Therefore, it might be pertinent to consider other methods of motivating donors to 
donate.  
The regulatory system does provide some reassurance in terms of donor 
confidentiality and rights to feedback. But its application is unfortunately vague and 
complex for the development of stem cell medicines, which involves incomplete 
anonymisation and compilations of genetic information. 
3 Encouraging Responsible Manufacturing Practice 
A number of positive steps have been taken to encourage responsible manufacturing 
practice in the UK.  The UK Stem Cell Bank has signalled that it intends to work in 
partnership with industry to help them innovate efficiently, as well as to understand 
their ethical responsibilities. Furthermore, policymakers are aware of the importance 
of a level playing field99 and have given industry opportunities to contribute to 
consultations. Together with the extensive range of standards, these steps go a long 
way towards maintaining an effective climate of respect and cooperation with the 
regulators. Maintaining this balance in practice will not be easy. Several critical issues 
are yet to be navigated. The authorities need to decide how they will check whether 
guidelines are being observed, and what they will do when they first notice that a 
licensee is not observing the legislation or guidelines. If the line they take is too 
tough, companies may cease cooperating and look more aggressively for ways to 
avoid the regulatory pinch or abandon the technology. If too soft, industry may come 
to regard ethical responsibilities as optional. Another issue yet to be tackled with 
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vigour is biomedical companies’ ethical duty to share the profits that derive in part 
from altruistic donations by members of the public. 
4 A Final Word on Stem Cell Exceptionalism 
Academic debate on the regulation of stem cell medicine is remarkable for its 
scarcity, but does this mean the issues are extraordinary and in urgent need of 
legislators’ attention? We think this conclusion would be too strong. The scientific 
progress associated with stem cell medicine does not enter a regulatory vacuum. The 
law is designed to adapt to changing social circumstance. Nevertheless, there are 
several emerging regulatory issues that deserve closer scrutiny. None of these issues 
are unique to the regulation of stem cell medicine but quite a number are uncommonly 
encountered; for instance the s 54(7) exemption in the HTA, the new Stem Cell Bank 
with regulatory powers but no statutory standing, the interpretation of morality-based 
prohibitions on patenting in intellectual property law; unusual market dynamics and 
unfamiliar scientific risks (in particular in relation to autologous tissue transplants). In 
addition, we observed a number of issues that regularly arise in other fields of biolaw 
but which are no less important for being seen before. In summary, scant attention to 
methods of enforcement and compliance, vagueness about the criteria for market 
approval owing to the uncertainty surrounding the borderline between a product and a 
device, data protection law, information required for valid consent, the exceptions to 
the ‘no property in the body or body parts’ rule, and ethical debate about the extent to 
which the law should recognise donors’ proprietary, economic and other rights in cell 
lines derived from their tissue. Hopefully these issues will be the focus of further 
inquiry by scholars from a wide variety of backgrounds without giving rise to a new 
kind of regulatory exceptionalism.  
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http://pharmacos.eudra.org/F3/human-tissue/index.htm (accessed 07/02/05). 
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